(Source: June 2008; Stemedica Cell Technologies, Inc.) View video of the event>>>
Leaders from Stemedica Cell Technologies (Stemedica), a San Diego-based adult stem cell research and development company, and the Gyeonggi Province, Republic of Korea’s government, gathered in Palo Alto, California to sign a Memorandum of Understanding that will stimulate economic development and technological advancement between the parties.
“This is an important relationship for the Gyeonggi Province.” said Governor Moon-Soo Kim, “We are delighted to have Stemedica’s experience and expertise invested in our Province and country, and we are ready to help them build their Korean investment into a regional success story.” The Gyeonggi Province is the largest province in the Republic of Korea, with Seoul as the Province’s largest city.
“This Memorandum will allow Stemedica to bring our adult stem cell research and know-how to Korea while, at the same time, providing our organization with a wealth of intellectual and organizational resources. We are very pleased with this agreement between Stemedica and the Province.” said Roger J. Howe, PhD, Executive Chairman of Stemedica.
Stemedica’s commitment includes the completion and hiring of area residents for its new laboratory and manufacturing facility located in the Province’s Ahn San Techno Park. “The Memorandum outlines a commitment by the Governor of the Province to introduce and otherwise help develop academic, regulatory, corporate and funding relationships for Stemedica”, said Maynard A. Howe, PhD, CEO & Vice Chairman of Stemedica. “The Governor’s strong and pro-active support will provide significant value to Stemedica as we work to establish our presence in Korea and across the Asian Pacific region.”
The event was attended by a delegation from the Gyeonggi Province, international media and Stemedica leadership including CEO and Vice Chairman Maynard A. Howe, PhD, Executive Chairman Roger Howe and Board Members William Maloney, MD (Professor and Chairman of the Department of Orthopaedic Surgery Stanford University) and Neil Kurtz, MD, (CEO of TorreyPines Therapeutics).
For more information regarding this Media Release or Stemedica Cell Technologies, contact Dave McGuigan at firstname.lastname@example.org.